European Society of Cardiology 2023, treatment guidelines suggest metformin, SGLT2 inhibitors, or GLP-1 receptor agonists based on individual patient profiles and risk factors
Clinical trial data consistently show that these medications produce small to moderate improvements in several lipid parameters, with the magnitude of effect varying by specific agent and patient population
Personalised weekly meal plans Generate your meal plan in seconds based on your likes and preferences, with printable recipe cards
doi: 10.1210/endo.142.5.8128 50 BnemannMGerhardsteinBLGaoTHoseyMM
While Eli Lilly and Company has warning labels about the most common side effects of their GIP/GLP-1 medications, the language on these labels may not have provided adequate warnings about serious GI health risks such as stomach paralysis, intestinal blockages, bowel obstruction, or frequent and excessive vomiting
GLP-1s are helping users achieve their health goals, but the popular weight-loss drugs are also manifesting unanticipated positive health trends, creating new opportunities and challenges for CPG companies, according to a report by Acosta Group